 Erin Guest
Concepts (148)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 10 | 2023 | 60 | 3.370 |
Why?
| | Antineoplastic Agents | 3 | 2022 | 57 | 1.470 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 4 | 2022 | 7 | 1.210 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 4 | 2021 | 71 | 1.120 |
Why?
| | Leukemia, Myeloid, Acute | 5 | 2023 | 114 | 0.960 |
Why?
| | Hematopoietic Stem Cell Transplantation | 3 | 2023 | 50 | 0.830 |
Why?
| | Asparaginase | 3 | 2020 | 15 | 0.810 |
Why?
| | Polyethylene Glycols | 3 | 2020 | 12 | 0.810 |
Why?
| | Mammaplasty | 1 | 2021 | 4 | 0.790 |
Why?
| | Goals | 1 | 2021 | 8 | 0.790 |
Why?
| | Breast Neoplasms | 1 | 2021 | 38 | 0.780 |
Why?
| | Biomarkers, Tumor | 2 | 2021 | 61 | 0.770 |
Why?
| | Humans | 22 | 2023 | 6599 | 0.740 |
Why?
| | Lymphoma, T-Cell | 1 | 2019 | 3 | 0.730 |
Why?
| | Desensitization, Immunologic | 1 | 2019 | 19 | 0.720 |
Why?
| | Infant | 11 | 2022 | 1396 | 0.640 |
Why?
| | Multicenter Studies as Topic | 1 | 2017 | 17 | 0.620 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2017 | 10 | 0.620 |
Why?
| | Molecular Targeted Therapy | 1 | 2017 | 11 | 0.600 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2017 | 62 | 0.600 |
Why?
| | Primary Health Care | 1 | 2014 | 44 | 0.500 |
Why?
| | Prognosis | 5 | 2023 | 209 | 0.460 |
Why?
| | Neoplasms | 1 | 2014 | 119 | 0.430 |
Why?
| | Male | 9 | 2023 | 3197 | 0.410 |
Why?
| | Hemoglobins, Abnormal | 1 | 2011 | 1 | 0.400 |
Why?
| | alpha-Globins | 1 | 2011 | 1 | 0.400 |
Why?
| | Mutation, Missense | 1 | 2011 | 24 | 0.390 |
Why?
| | Female | 9 | 2023 | 3436 | 0.380 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2020 | 27 | 0.360 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2020 | 33 | 0.360 |
Why?
| | Treatment Outcome | 3 | 2022 | 624 | 0.350 |
Why?
| | Child | 10 | 2023 | 3146 | 0.330 |
Why?
| | Adolescent | 6 | 2023 | 2087 | 0.260 |
Why?
| | Gene Rearrangement | 2 | 2022 | 8 | 0.260 |
Why?
| | Doxorubicin | 2 | 2020 | 17 | 0.230 |
Why?
| | Myeloproliferative Disorders | 1 | 2023 | 11 | 0.230 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2023 | 2 | 0.230 |
Why?
| | Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 3 | 0.230 |
Why?
| | Salvage Therapy | 2 | 2020 | 8 | 0.230 |
Why?
| | Histone-Lysine N-Methyltransferase | 2 | 2021 | 9 | 0.230 |
Why?
| | Follow-Up Studies | 3 | 2020 | 315 | 0.230 |
Why?
| | Germ Cells | 1 | 2022 | 5 | 0.220 |
Why?
| | Clinical Trials as Topic | 1 | 2022 | 44 | 0.210 |
Why?
| | Neoplasms, Muscle Tissue | 1 | 2021 | 1 | 0.200 |
Why?
| | Tongue Neoplasms | 1 | 2021 | 2 | 0.200 |
Why?
| | Protein Kinase Inhibitors | 1 | 2021 | 5 | 0.200 |
Why?
| | Risk Factors | 3 | 2021 | 460 | 0.200 |
Why?
| | Mastectomy | 1 | 2021 | 1 | 0.200 |
Why?
| | Pilot Projects | 2 | 2020 | 124 | 0.190 |
Why?
| | PTEN Phosphohydrolase | 1 | 2020 | 7 | 0.190 |
Why?
| | Neoplastic Stem Cells | 1 | 2020 | 10 | 0.190 |
Why?
| | Wnt Proteins | 1 | 2020 | 11 | 0.190 |
Why?
| | beta Catenin | 1 | 2020 | 9 | 0.190 |
Why?
| | Cerebrospinal Fluid Shunts | 1 | 2019 | 3 | 0.180 |
Why?
| | Adult | 2 | 2021 | 1233 | 0.180 |
Why?
| | Communicable Diseases | 1 | 2019 | 9 | 0.180 |
Why?
| | Quality of Life | 1 | 2021 | 131 | 0.180 |
Why?
| | Disease Outbreaks | 1 | 2019 | 30 | 0.180 |
Why?
| | Leukapheresis | 1 | 2018 | 1 | 0.170 |
Why?
| | Citric Acid | 1 | 2018 | 2 | 0.170 |
Why?
| | Heparin | 1 | 2018 | 7 | 0.170 |
Why?
| | Prospective Studies | 1 | 2021 | 508 | 0.170 |
Why?
| | Middle Aged | 1 | 2021 | 648 | 0.170 |
Why?
| | Glucose | 1 | 2018 | 22 | 0.170 |
Why?
| | T-Lymphocytes | 1 | 2018 | 31 | 0.170 |
Why?
| | Anticoagulants | 1 | 2018 | 17 | 0.170 |
Why?
| | Child, Preschool | 5 | 2021 | 1459 | 0.160 |
Why?
| | Family Relations | 1 | 2017 | 3 | 0.160 |
Why?
| | Proportional Hazards Models | 1 | 2017 | 34 | 0.150 |
Why?
| | Remission Induction | 1 | 2017 | 25 | 0.150 |
Why?
| | Kaplan-Meier Estimate | 1 | 2017 | 28 | 0.150 |
Why?
| | Aminoglycosides | 1 | 2017 | 17 | 0.150 |
Why?
| | Hepatic Veno-Occlusive Disease | 1 | 2017 | 6 | 0.150 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2017 | 31 | 0.150 |
Why?
| | Combined Modality Therapy | 1 | 2017 | 51 | 0.150 |
Why?
| | Epigenesis, Genetic | 1 | 2017 | 64 | 0.150 |
Why?
| | Genetic Testing | 1 | 2017 | 74 | 0.140 |
Why?
| | Obesity | 1 | 2017 | 124 | 0.140 |
Why?
| | Emergencies | 1 | 2014 | 11 | 0.130 |
Why?
| | Diagnosis, Differential | 1 | 2014 | 74 | 0.130 |
Why?
| | Leukemia | 2 | 2012 | 17 | 0.120 |
Why?
| | RNA Polymerase II | 1 | 2012 | 2 | 0.110 |
Why?
| | Transcriptional Elongation Factors | 1 | 2012 | 2 | 0.110 |
Why?
| | Recurrence | 2 | 2023 | 115 | 0.110 |
Why?
| | Heme | 1 | 2011 | 1 | 0.100 |
Why?
| | Models, Molecular | 1 | 2011 | 14 | 0.100 |
Why?
| | Protein Structure, Tertiary | 1 | 2011 | 14 | 0.100 |
Why?
| | Binding Sites | 1 | 2011 | 26 | 0.100 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 2011 | 41 | 0.100 |
Why?
| | Anemia | 1 | 2011 | 25 | 0.100 |
Why?
| | Mitoxantrone | 2 | 2020 | 6 | 0.090 |
Why?
| | Vincristine | 2 | 2020 | 8 | 0.090 |
Why?
| | Bortezomib | 2 | 2020 | 10 | 0.090 |
Why?
| | Survival Rate | 2 | 2020 | 84 | 0.090 |
Why?
| | Dexamethasone | 2 | 2020 | 30 | 0.090 |
Why?
| | United States | 2 | 2022 | 646 | 0.090 |
Why?
| | Young Adult | 2 | 2023 | 652 | 0.090 |
Why?
| | Infant, Newborn | 2 | 2021 | 790 | 0.080 |
Why?
| | Retrospective Studies | 2 | 2022 | 1251 | 0.070 |
Why?
| | Neoplasm, Residual | 1 | 2023 | 8 | 0.060 |
Why?
| | Transplantation, Homologous | 1 | 2023 | 20 | 0.060 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2022 | 4 | 0.060 |
Why?
| | Azacitidine | 1 | 2022 | 4 | 0.060 |
Why?
| | Antigens, CD19 | 1 | 2022 | 2 | 0.060 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2022 | 7 | 0.060 |
Why?
| | Immunotherapy | 1 | 2022 | 14 | 0.050 |
Why?
| | Anthracyclines | 1 | 2021 | 7 | 0.050 |
Why?
| | Transcription, Genetic | 2 | 2012 | 44 | 0.050 |
Why?
| | Cytarabine | 1 | 2021 | 24 | 0.050 |
Why?
| | Risk Assessment | 1 | 2021 | 130 | 0.050 |
Why?
| | Time Factors | 1 | 2021 | 241 | 0.050 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2020 | 8 | 0.050 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2020 | 14 | 0.050 |
Why?
| | Tumor Cells, Cultured | 1 | 2020 | 24 | 0.050 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2020 | 9 | 0.050 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2020 | 9 | 0.050 |
Why?
| | Mice, Knockout | 1 | 2020 | 54 | 0.050 |
Why?
| | Cell Proliferation | 1 | 2020 | 55 | 0.050 |
Why?
| | Apoptosis | 1 | 2020 | 43 | 0.050 |
Why?
| | Logistic Models | 1 | 2019 | 91 | 0.050 |
Why?
| | Bacterial Infections | 1 | 2019 | 27 | 0.040 |
Why?
| | Case-Control Studies | 1 | 2019 | 202 | 0.040 |
Why?
| | Mice | 1 | 2020 | 290 | 0.040 |
Why?
| | Immunotherapy, Adoptive | 1 | 2018 | 6 | 0.040 |
Why?
| | Leukocytes, Mononuclear | 1 | 2018 | 11 | 0.040 |
Why?
| | Animals | 1 | 2020 | 563 | 0.040 |
Why?
| | Perception | 1 | 2017 | 9 | 0.040 |
Why?
| | Risk | 1 | 2017 | 40 | 0.040 |
Why?
| | Survivors | 1 | 2017 | 17 | 0.040 |
Why?
| | Comorbidity | 1 | 2017 | 61 | 0.040 |
Why?
| | Pediatrics | 1 | 2018 | 170 | 0.040 |
Why?
| | Parents | 1 | 2017 | 149 | 0.030 |
Why?
| | Surveys and Questionnaires | 1 | 2017 | 290 | 0.030 |
Why?
| | Positive Transcriptional Elongation Factor B | 1 | 2012 | 1 | 0.030 |
Why?
| | Genes, myc | 1 | 2012 | 2 | 0.030 |
Why?
| | RNA, Neoplasm | 1 | 2012 | 5 | 0.030 |
Why?
| | Jurkat Cells | 1 | 2012 | 4 | 0.030 |
Why?
| | Multiprotein Complexes | 1 | 2012 | 5 | 0.030 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2012 | 4 | 0.030 |
Why?
| | Repressor Proteins | 1 | 2012 | 12 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2012 | 30 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2012 | 12 | 0.030 |
Why?
| | Base Sequence | 1 | 2012 | 76 | 0.030 |
Why?
| | Nuclear Proteins | 1 | 2012 | 45 | 0.030 |
Why?
| | Cell Line | 1 | 2012 | 80 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2012 | 107 | 0.030 |
Why?
| | Gene Expression Regulation | 1 | 2012 | 98 | 0.030 |
Why?
| | Translocation, Genetic | 1 | 2010 | 4 | 0.020 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|